Comparing the current results to its competitors, Surmodics Inc reported Revenue decrease in the 3 quarter 2025 year on year by -2.55 %, despite the revenue increase by the most of its competitors of 5.57 %, recorded in the same quarter.
Surmodics Inc 's Comment on Competition and Industry Peers
The company operates in the vascular intervention segment of the medical device market, competing with global leaders in this field. It develops vascular intervention medical devices that incorporate proprietary performance coatings and technologies. The company licenses its coating products to established manufacturers, some of which compete with larger firms. Key competitive factors include regulatory approval, marketing and sales capabilities, and pricing pressures.
May 1, 2024
Distinguished in the healthcare industry for their continuous innovation, Surmodics, Inc., headquartered in Eden Prairie, Minnesota, reported total revenue of $32.0 million for the second quarter of the fiscal year 2024, showcasing an outstanding 18% increase on a year-to-year basis. This remarkable growth becomes even more noteworthy when considering total revenue excluding revenue from Surmodics SurVeil drug-coated balloon (DCB) product. With an ever-growing portfolio of medical devices and in vitro diagnostic technologies, Surmodics continues to create value across a broad range of healthcare applications. The reported financial results reflect the ongoing solidification of the Eden Prairie-based organiz...
Surmodics, a renowned provider of medical device and in vitro diagnostic technologies, recently presented the noteworthy 24-month data from the SWING Trial at the prestigious 50th annual VEITH Symposium in New York. The trial evaluated the safety and performance of the Sundance Sirolimus Drug-Coated Balloon (DCB), marking an important milestone in the healthcare industry. In addition to this achievement, Surmodics Inc also reported a revenue increase in the first quarter of 2023, although it fell slightly below the average revenue growth of its competitors. In this article, we will delve into these facts and analyze their impact on the company. The SWING Trial: The SWING Trial is a signific...
Edwards Lifesciences Corporations business model focuses on the development and commercialization of advanced medical technologies that enhance the diagnosis and treatment of heart disease, emphasizing innovative heart valves and critical care monitoring solutions. The company serves a diverse customer base, including hospitals and direct-to-patient markets, with a strong commitment to improving patient outcomes and quality of life.
Integra Lifesciences Holdings Corp's business model revolves around developing, manufacturing, and selling medical devices and instruments to healthcare providers.
Ir med Inc's business model involves providing innovative medical technologies and solutions to the healthcare industry. The company focuses on developing and commercializing advanced medical devices that aim to improve patient outcomes and enhance overall healthcare management.
Livanova Plc is a global medical technology company that focuses on developing and delivering innovative solutions for patients with cardiovascular diseases and neuropsychiatric disorders. Through their diverse portfolio, they offer products and therapies that encompass surgical heart valves, cardiac rhythm management, and neuromodulation. Livanova adopts a patient-centric approach, collaborating with healthcare professionals to improve patient outcomes and enhance quality of life.
Medtronic Plc operates a global business model centered on the development and distribution of advanced medical technologies across four key segments: Cardiac and Vascular, Minimally Invasive Therapies, Restorative Therapies, and Diabetes. The company emphasizes innovation and collaboration with healthcare providers to enhance patient outcomes and drive efficiency within healthcare systems.
Sources:
Surmodics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Surmodics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
